03:32 PM EST - Nuvo Pharmaceuticals Inc. : Announced that it has closed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals Inc. Benefits include: Immediately and significantly accretive to revenue and adjusted EBITDA: Revenue diversification from product sales and royalty revenues; The move provides Canadian platform with national sales infrastructure and an ability to launch and commercialize additional products. Significant cash flow from U.S. and international royalties of global Vimovo® sales. Nuvo Pharmaceuticals Inc.
shares T.NRI are trading down $0.11 at $2.01.
